Showing results (1781-1790 of 2,011) with videos related to
Sort By:
Pageof 202
Nature|June 1, 2001
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's diseaseJ P Hugot, M Chamaillard, H Zouali, et al.Nature Medicine|February 3, 2026
High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trialRichard S Finkel, Thomas O Crawford, Eugenio Mercuri, et al.Cancer Immunology, Immunotherapy : CII|January 9, 2022
Combination immunotherapy including OncoVEX<sup>mGMCSF</sup> creates a favorable tumor immune micro-environment in transgenic BRAF murine melanomaRobyn D Gartrell, Zoë Blake, Emanuelle M Rizk, et al.Bioresource Technology|July 29, 2010
The utility of Shewanella japonica for microbial fuel cellsJustin C Biffinger, Lisa A Fitzgerald, Ricky Ray, et al.Neuromuscular Disorders : NMD|October 30, 2016
Developmental milestones in type I spinal muscular atrophyRoberto De Sanctis, Giorgia Coratti, Amy Pasternak, et al.Journal of Neuropathology and Experimental Neurology|April 9, 2014
Clinical, pathologic, and mutational spectrum of dystroglycanopathy caused by LARGE mutationsKatherine G Meilleur, Kristen Zukosky, Livija Medne, et al.The New England Journal of Medicine|May 22, 2008
Intensity of renal support in critically ill patients with acute kidney injury, Paul M Palevsky, Jane Hongyuan Zhang, et al.Neurology. Clinical Practice|September 3, 2021
Nusinersen Treatment in Adults With Spinal Muscular AtrophyTina Duong, Connie Wolford, Michael P McDermott, et al.Muscle & Nerve|May 10, 2018
Longitudinal timed function tests in Duchenne muscular dystrophy: ImagingDMD cohort natural historyHarneet Arora, Rebecca J Willcocks, Donovan J Lott, et al.Journal of Neuromuscular Diseases|June 6, 2018
Evaluator Training and Reliability for SMA Global Nusinersen Trials1Allan M Glanzman, Elena S Mazzone, Sally Dunaway Young, et al.Pageof 202